Skevofilax v. Aventis Pasteur, Inc.

891 A.2d 416, 167 Md. App. 1, 2006 Md. App. LEXIS 13
CourtCourt of Special Appeals of Maryland
DecidedFebruary 1, 2006
DocketNo. 2526
StatusPublished
Cited by2 cases

This text of 891 A.2d 416 (Skevofilax v. Aventis Pasteur, Inc.) is published on Counsel Stack Legal Research, covering Court of Special Appeals of Maryland primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Skevofilax v. Aventis Pasteur, Inc., 891 A.2d 416, 167 Md. App. 1, 2006 Md. App. LEXIS 13 (Md. Ct. App. 2006).

Opinion

WOODWARD, J.

In April 2003, appellants, Helen and John Skevofilax, individually and on behalf of their son, Michael Skevofilax, a minor, filed suit in the Circuit Court for Baltimore City against appellees, several defendants involved in the manufacture of pediatric vaccines or ingredients used in those vaccines.1 Appellants claimed that mercury in the vaccines caused Michael neurological injuries. On December 21, 2004, [7]*7the circuit court granted summary judgment to appellees after Michael’s only expert witness on specific causation abruptly ended his participation in the case. In this appeal, appellants argue that the trial court abused its discretion in denying their motion to dismiss the case without prejudice pursuant to Maryland Rule 2-506(b). For the reasons set forth in this opinion, we will reverse the court’s judgment.

BACKGROUND

Appellants filed suit in the circuit court on April 14, 2003, when Michael was five years old.2 Michael has autism. Appellants allege that thimerosal, a preservative containing mercury, caused Michael’s autism, and that he was exposed to thimerosal when he was vaccinated as a baby. They assert, inter alia, that appellees negligently and fraudulently manufactured, marketed, and distributed their products, and as a direct and proximate result, Michael ingested poisonous mercury and suffered permanent neurological, developmental, and behavioral injuries, including his autism.3 The Skevofilaxes’ lawsuit is representative of the many vaccine injury cases throughout the country currently in litigation.

On July 11, 2003, appellees had the case removed to the U.S. District Court for the District of Maryland. Two months later, however, on September 5, 2003, the case was returned to the circuit court. The court convened a hearing on November 13, 2003, at which the parties discussed a schedule for discovery and trial. The court then issued a scheduling order that directed, inter alia, the completion of fact discovery by July 30, 2004, identification of appellants’ expert witnesses by [8]*8September 1, 2004, identification of appellees’ expert witnesses by November 1, 2004, completion of expert discovery by December 15, 2004, filing of all dispositive motions no later than February 15, 2005, and the start of trial on May 2, 2005.

The parties began discovery. According to appellees, they deposed thirteen witnesses and prepared an additional nineteen for deposition by appellants. The parties also exchanged and responded to interrogatories and requests for production of documents. The long list of witnesses and the volume of materials soon led the Skevofilaxes to doubt their ability to meet the fact discovery deadline of July 30, 2004. On June 15, 2004, they requested an extension, which the court granted on July 16, 2004, with the filing of an Amended Scheduling Order. The new scheduling order extended the deadline for fact discovery until December 15, 2004, the deadline for identification of appellants’ expert witnesses by two weeks, to September 15, 2004, and the deadline for identification of appellees’ expert witnesses by one week, to November 8, 2004. The expert discovery deadline remained December 15, 2004. However, the court denied appellants’ request to move the trial date to September 19, 2005, because the presiding judge was scheduled to end his rotation in the civil department on August 31, 2005, and he wanted the trial completed by that time.

On August 2, 2004, the Skevofilaxes requested a modification of the Amended Scheduling Order. They sought and received, in the Second Amended Scheduling Order, three more weeks to identify their expert witnesses, with a new deadline set at October 8, 2004. The expert discovery deadline was extended five days to December 20, 2004.

Discovery continued with appellees retaining expert witnesses and pursuing medical examinations of Michael. Per the Second Amended Scheduling Order, on October 8, 2004, appellants identified eight expert witnesses, four on liability and four on damages. One of the Skevofilaxes’ liability experts was expected to testify on specific causation, that is, to express an opinion on how Michael’s vaccines caused his [9]*9autism. This expert was James Jeffrey Bradstreet, M.D., a family practitioner in Florida.

Appellants faced another obstacle towards the end of October when they learned that Dr. Bradstreet could not formulate a medical opinion as to the cause of Michael’s autism without the results of certain tests that would aid him in determining Michael’s “genomic susceptibility” to thimerosal. Laboratory clinicians at the University of Arkansas were scheduled to run these tests, but “exigent circumstances” caused them to delay the completion of testing by “at least 30 to 60 days.” Without the test results, Dr. Bradstreet could not formulate an expert opinion, and without Dr. Bradstreet’s expert opinion, appellants could not present him for deposition by appellees. By letter dated October 26, 2004, appellants’ counsel informed appellees that Dr. Bradstreet would not be prepared for his deposition, which, per the Second Amended Scheduling Order, had to be taken no later than November 5, 2004.

On October 29, 2004, appellants requested a continuance of the trial, or, alternatively, dismissal without prejudice. On November 10, 2004, the court convened a hearing, at which it declined to grant a continuance or to dismiss the case without prejudice. Instead, the court directed the parties to collaborate on a new scheduling time line, or, if they could not agree, to submit separate proposals. Based on the parties’ proposals, on November 19, 2004, the court issued a Third Amended Scheduling Order. This order directed that Dr. Bradstreet be deposed no later than December 3, 2004, without questioning about the genetic tests underway in Arkansas, and then again by January 14, 2005, if the results from those tests became available. The expert discovery deadline was extended to January 22, 2005, but the filing date for dispositive motions, February 15, 2005, and the trial date, May 2, 2005, remained the same.

Appellants did not have much time to follow the Third Amended Scheduling Order because shortly after it was entered, appellants’ counsel learned that Dr. Bradstreet was ending his participation in the case. Counsel immediately [10]*10notified the court and appellees’ counsel of this dramatic development by letter dated November 28, 2004.

On December 1, 2004, appellants renewed their motion of October 29, 2004, to dismiss all claims without prejudice, pursuant to Rule 2-506(b). Attached to the renewed motion was an affidavit of appellants’ counsel stating that Dr. Bradstreet ended his participation “because of professional and personal commitments and time constraints.” Also on December 1, 2004, appellees filed motions for summary judgment on the grounds that without Dr. Bradstreet, appellants had no evidence of specific causation, a required element of their claims.4 On December 21, 2004, following a hearing, the court denied appellants’ motion and granted the appellees’ motions.5 “Critical” to the court’s decision on appellants’ motion was the “extensive” discovery that the parties had completed and “the time, effort and expense” that the parties already had expended on preliminary motions.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In re: David P.
170 A.3d 818 (Court of Special Appeals of Maryland, 2017)
Aventis Pasteur, Inc. v. Skevofilax
914 A.2d 113 (Court of Appeals of Maryland, 2007)

Cite This Page — Counsel Stack

Bluebook (online)
891 A.2d 416, 167 Md. App. 1, 2006 Md. App. LEXIS 13, Counsel Stack Legal Research, https://law.counselstack.com/opinion/skevofilax-v-aventis-pasteur-inc-mdctspecapp-2006.